bioAffinity Technologies Hits New 52-Week Low at $2.05

bioAffinity Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 2.05 on November 4, 2025. This significant drop highlights the company's ongoing struggles, as it has experienced a one-year performance decline of 7.52%, contrasting sharply with the S&P 500's gain of 19.89% during the same period.
The company's market capitalization stands at approximately USD 7 million, reflecting its microcap status. bioAffinity Technologies has faced challenges in generating positive financial metrics, with a negative operating cash flow of USD -7.68 million and a return on capital employed (ROCE) of -1,802.45%. Additionally, the company's net sales for the latest quarter were reported at USD 1.27 million, indicating a tough market environment.

Despite a historical high of USD 46.53, the stock's recent performance underscores a broader trend of underperformance, with a staggering return of -94.40% over the past year. The company's financial health is further illustrated by its weak debt servicing capability, evidenced by a poor EBIT to interest ratio of -5.67. As bioAffinity Technologies navigates these financial hurdles, its current stock price reflects the challenges it faces in the competitive biotechnology landscape.